Prevalence of Human Papillomavirus Infection and Cervical Pathology in Women with Different HIV Statuses

Cover Page

Cite item

Full Text

Abstract

Human papillomavirus (HPV) genotype distribution HIV-infected women shows both similarities and distinct differences compared to HIV-negative women. A global meta-analysis of 5,578 HIV-positive women across multiple continents demonstrated HPV monoinfection prevalence of 36.3 % and multiple-type infections in 11.9 % of cases. This population therefore represents a high-risk group for cervical cancer development, presenting a significant public health challenge.

References

  1. Clifford G.M., Gonçalves M.A., Franceschi S. HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006; 20(18): 2337-44.-DOI: https://doi.org/10.1097/01.aids.0000253361.63578.14.
  2. Okunade K.S. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020; 40(5): 602-608.-DOI: https://doi.org/10.1080/01443615.2019.1634030.
  3. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mor tality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394-424.-DOI: https://doi.org/10.3322/caac.21492.
  4. Мухсинзода Н.А., Баротова Б.У., Киёбекова Г.А., Турсу нов Р.А. Первый опыт тестирования на вирус папилломы человека в Республике Таджикистан. Вопросы онкологии.2024; 70(3): 564-568.-DOI: https://doi.org/10.37469/0507-3758-2024-70-3-564-568. [Muhsinzoda N.A., et al. The first experience of testing for human papillomavirus in the Republic of Tajikistan. Voprosy onkologii = Oncology issues. 2024; 70(3): 564-568.-DOI: https://doi.org/10.37469/0507-3758-2024-70-3-564-568 (In Rus)].
  5. Мухсинзода Н.А., Мухсинзода Г.М., Саидзода Ф.Б., Тур сунов Р.А. Подготовка системы здравоохранения к ру тинной вакцинации против вируса папилломы человека. Евразийский научно-медицинский журнал «Сино». 2024; 5(1): 5-20. [Muhsinzoda N.A., et al. Preparing the health care system for routine vaccination against human papillo mavirus. Yevraziyskiy Nauchno-Meditsinskiy Zhurnal «Sino» ꞊ Eurasian Scientific and Medical Journal “Sino”. 2024; 5(1): 5-20. (In Rus)].
  6. Мирзоев А.С., Назурдинов А.Б., Турсунов Р.А., Азизов З.А. Эпидемиологические аспекты влияния вакцины против вируса папилломы человека в профилактике рака шейки матки в глобальном масштабе и рекомендации по ее внедрению в Таджикистане. Вестник Смоленской государственной медицинской академии. 2019: 18(3): 139-147. [Mirzoev A.S., et al. Epidemiological aspects of the im pact of the human papillomavirus vaccine in the prevention of cervical cancer on a global scale and recommendations for its implementation in Tajikistan. Vestnik Smolenskoy gosudarst vennoy meditsinskoy akademii = Bulletin of the Smolensk State Medical Academy. 2019; 18(3): 139-147. (In Rus)].
  7. Abdi M., Tamiru A., Tilahun T., et al. Factors associated with human papillomavirus infections among women living with HIV in public health facilities in Western Oromia, Ethiopia. BMC Womens Health. 2024; 24(1): 423.-DOI: https://doi.org/10.1186/s12905-024-03249-y.
  8. Monteiro J.C., Fonseca R.B., Ferreira T.C., et al. Prevalence of High-risk HPV in HIV-infected women from Belem, Para, Amazon Region of Brazil: A cross-sectional study. Fron tiers in Public Health. 2021; 9(6): 1-8.-DOI: https://doi.org/10.3389/fpubh.2021.649152.
  9. Shrestha S., Sudenga S.L., Smith J., et al. The impact of high ly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infectious Diseases. 2010; 10: 295-295.-DOI: https://doi.org/10.1186/1471-2334-10-295.
  10. Bangquan L., Jiabao Z., Wanyu W., et al. Identification of tumor microenvironment and DNA methylation-related prog nostic signature for predicting clinical outcomes and thera peutic responses in cervical cancer. Front Mol Biosci. 2022; 9.-DOI: https://doi.org/10.3389/fmolb.2022.872932.
  11. Шипулина О.Ю., Попова А.А., Кравченко А.В., et al. Распространение высокоонкогенных генотипов вируса папилломы человека у ВИЧ-позитивных и ВИЧ-нега тивных женщин. Инфекционные болезни. 2016; 14(4): 26-30.-DOI: https://doi.org/10.20953/1729-9225-2016-4-26-30. [Shipulina O. Yu., Popova A. A., Kravchenko A. V., et al. Prevalence of highly oncogenic genotypes of human papillomavirus in HIV-positive and HIV-negative women. Infectious Diseases. 2016; 14(4): 26-30.-DOI: https://doi.org/10.20953/1729-9225-2016-4-26-30. (In Rus)].
  12. Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical can cer. The Lancet. 2019; 393(0167): 169-182.-DOI: https://doi.org/10.1016/S0140-6736(18)32470-X.
  13. Jolly P.E., Mthethwa-Hleta S., Padilla L.A., et al. Screen ing, prevalence, and risk factors for cervical lesions among HIV-positive and HIV-negative women in Swaziland. BMC Public Health. 2017; 17(218): 4120-4123.-DOI: https://doi.org/10.1186/s12889-017-4120-3.
  14. Megersa T., Dango S., Kumsa K., et al. Prevalence of high risk human papillomavirus infections and associated factors among women living with HIV in Shashemene town public health facilities, Southern Ethiopia. BMC Women’s Health. 2023; 23(1): 125.-DOI: https://doi.org/10.1186/s12905-023-02279-2.
  15. Taku O., Businge C.B., Mdaka M.L., et al. Human papillo mavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South doi: 10.37469/0507-3758-2025-71-6-OF-2282 Africa. Int J Infect Dis. 2020; 95: 176-182.-DOI: https://doi.org/10.1016/j.ijid.2020.02.051.
  16. Silva L.D., et al. High risk of human papillomavirus and cervical lesions among women living with HIV/AIDS in the Brazilian Amazon, Brazil. Braz J Infectious Dis. 2015; 19: 557-562.-DOI: https://doi.org/10.1016/j.bjid.2015.07.001.
  17. Sycheva E., Nazarova N., Burmenskaya O., et al. The oc currence of human papillomavirus types in the formation of neoplastic transformation of the epithelium of the cervix in “lesser abnormalies”. Gynecology. 2020; 22: 19-22. -DOI: https://doi.org/10.26442/20795696.2020.1.200015.
  18. Файзулоев Е.Б., Каира А.Н., Узбеков Т.Р., et al. Распростра ненность папилломавирусов человека высокого и низкого онкогенного риска на территории Российской Федерации. Молекулярная генетика, микробиология и вирусология. 2021; 39(4): 39‑47.-DOI: https://doi.org/10.17116/molgen20213904139. [Faizuloev E.B., Kaira A.N., Uzbe kov T.R., et al. The prevalence of high and low risk human papillomaviruses in the Russian Federation. Molekulyarnaya genetika, mikrobiologiya i virusologiya = Molecular Genet ics, Microbiology and Virology. 2021; 39(4): 39‑47.-DOI: https://doi.org/10.17116/molgen20213904139 (In Rus)].
  19. Popova A., Shipulina O., Deulina M., et al. HPV infection among HIV-positive women in some coun-tries of Eastern Europe and Central Asia. J Intern AIDS Soc. 2018; 21(S8): 123-124.-DOI: https://doi.org/10.1002/jia2.25187.
  20. Прилепская Д.Р., Домонова Э.А., Попова А.А., et al. Ин формированность женщин с различным ВИЧ-статусом о папилломавирусной инфекции в странах Восточной Ев ропы и Центральной Азии. Здоровье населения и среда обитания – ЗНиСО. 2024; 32(11): 57-67.-DOI:https://doi.org/10.35627/2219-5238/2024-32-11-57-67. [Prilep skaya D.R., Domonova E.A., Popova A.A., et al. Awareness of women with different HIV status about human papilloma virus infection in the countries of Eastern Europe and Central Asia. Zdorov’ye Naseleniya i Sreda Obitaniya – ZNiSO = Population Health and Habitat - ZNiSO. 2024; 32(11): 57-67.-DOI: https://doi.org/10.35627/2219-5238/2024-32-11-57-67 (In Rus)].
  21. Турсунов Р.А., Канестри В.Г., Симонова Е.Г., Раичич Р.Р. Антиретровирусная терапия - новая эпоха профилакти ки ВИЧ-инфекции. ВИЧ-инфекция и иммуносупрессии. Санкт-Петербург. 2018; 10(1): 37-46.-DOI: https://doi.org/10.22328/2077-9828-2018-10-1-37-46. [Tursunov R.A., et al. Antiretroviral therapy - a new era of HIV in fection prevention. VICH-infektsiya i immunosupressii = HIV infection and immunosuppression. St. Petersburg. 2018; 10(1): 37-46.-DOI: https://doi.org/10.22328/2077-9828-2018-10-1-37-46 (In Rus)].
  22. Турсунов Р.А. Тенденция развития эпидемии ВИЧ-ин фекции в период пандемии COVID-19 в Республи ке Таджикистан. ВИЧ-инфекция и иммуносупрессии.Санкт-Петербург. 2025; 17(1): 34-40.-DOI: https://doi.org/10.22328/2077-9828-2025-17-1-62-68. [Tursun ov R.A. Trends in the development of the HIV epidemic during the COVID-19 pandemic in the Republic of Tajiki stan. VICH-infektsiya i immunosupressii = HIV infection and immunosuppression. St. Petersburg. 2025; 17(1): 34-40.-DOI: https://doi.org/10.22328/2077-9828-2025-17-1-62-68 (In Rus)].
  23. Muhsinzoda N.А., Yuan A.B., Wight E., Tursunov R.A. Cervical cancer visual screening experience in the Repub lic of Tajikistan. Journal “Gynecology, Obstetrics & Repro ductive Medicine”. 2024; 30(1): 55-61.-DOI: https://doi.org/10.21613/GORM.2023.1447.
  24. Absatou K.Y., Ouattara A., Tondé I., et al. Prevalence and factors associated with human papillomavirus infection among women living with HIV in Ouagadougou. Acta Scientific Microbiology. 2024; 03-09.-DOI: https://doi.org/10.31080/ASMI.2024.07.1366.
  25. Halichidis S., Aschie M., Cozaru G., Manea M. CMV and HIV coinfection in women from a region in Eastern Europe. Journal of Personalized Medicine. 2023; 13: 1539.-DOI: https://doi.org/10.3390/jpm13111539.
  26. Cambrea S., Aschie M., Resul G., et al. HPV and HIV coin fection in women from a southeast region of Romania - PI COPIV study. Medicina. 2022; 58: 760.-DOI: ttps://doi.org/10.3390/medicina58060760.
  27. Ajang Y., Ella E., Oguntayo A., Aminu M. Prevalence of human papillomavirus infection and its association with the risk of cervical cancer among HIV-positive women in plateau state, North-Central Nigeria. UMYU Journal of Microbiolo gy Research (UJMR). 2024; 9: 247-157.-DOI: https://doi.org/10.47430/ujmr.2491.016.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Problems in Oncology

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).